10-Q Filing
Filing Information
| Form Type | 10-Q |
| Accession Number | 0001628280-20-006966 |
| Period End Date | 20200331 |
| Filing Date | 20200507 |
| Fiscal Year | 2020 |
| Fiscal Period | Q1 |
| XBRL Instance | gh-03312020x10q_htm.xml |
Filing Contents
This filing contains the following financial statements:
Balance Sheet
74 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$143.23M | USD | Point-in-time |
| Cash and cash equivalents |
CashAndCashEquivalentsAtCarryingValue
|
$152.24M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$367.85M | USD | Point-in-time |
| Short-term marketable securities |
MarketableSecuritiesCurrent
|
$379.57M | USD | Point-in-time |
| Accounts receivable, net |
AccountsReceivableNetCurrent
|
$47.99M | USD | Point-in-time |
| Accounts receivable, net |
AccountsReceivableNetCurrent
|
$48.02M | USD | Point-in-time |
| Inventory |
InventoryNet
|
$25.15M | USD | Point-in-time |
| Common stock, par value (in usd per share) |
CommonStockParOrStatedValuePerShare
|
- | USD | Point-in-time |
| Inventory |
InventoryNet
|
$15.18M | USD | Point-in-time |
| Common stock, par value (in usd per share) |
CommonStockParOrStatedValuePerShare
|
- | USD | Point-in-time |
| Common stock, shares authorized (shares) |
CommonStockSharesAuthorized
|
350.00M | shares | Point-in-time |
| Common stock, shares authorized (shares) |
CommonStockSharesAuthorized
|
350.00M | shares | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$14.14M | USD | Point-in-time |
| Prepaid expenses and other current assets |
PrepaidExpenseAndOtherAssetsCurrent
|
$11.39M | USD | Point-in-time |
| Total current assets |
AssetsCurrent
|
$597.36M | USD | Point-in-time |
| Common stock, shares outstanding (shares) |
CommonStockSharesOutstanding
|
94.26M | shares | Point-in-time |
| Total current assets |
AssetsCurrent
|
$607.39M | USD | Point-in-time |
| Common stock, shares outstanding (shares) |
CommonStockSharesOutstanding
|
94.51M | shares | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$268.78M | USD | Point-in-time |
| Common stock, shares issued (shares) |
CommonStockSharesIssued
|
94.51M | shares | Point-in-time |
| Long-term marketable securities |
MarketableSecuritiesNoncurrent
|
$238.21M | USD | Point-in-time |
| Common stock, shares issued (shares) |
CommonStockSharesIssued
|
94.26M | shares | Point-in-time |
| Assets |
Assets
|
$948.17M | USD | Point-in-time |
| Assets |
Assets
|
$962.53M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$43.67M | USD | Point-in-time |
| Property and equipment, net |
PropertyPlantAndEquipmentNet
|
$46.69M | USD | Point-in-time |
| Liabilities |
Liabilities
|
$117.55M | USD | Point-in-time |
| Right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$29.14M | USD | Point-in-time |
| Liabilities |
Liabilities
|
$114.54M | USD | Point-in-time |
| Right-of-use assets |
OperatingLeaseRightOfUseAsset
|
$30.13M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$17.68M | USD | Point-in-time |
| Intangible assets, net |
IntangibleAssetsNetExcludingGoodwill
|
$8.52M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$3.29M | USD | Point-in-time |
| Goodwill |
Goodwill
|
$3.29M | USD | Point-in-time |
| Capitalized license fees |
CapitalizedLicenseFees
|
$60.00K | USD | Point-in-time |
| Capitalized license fees |
CapitalizedLicenseFees
|
$6.89M | USD | Point-in-time |
| Other assets |
OtherAssetsNoncurrent
|
$4.88M | USD | Point-in-time |
| Other assets |
OtherAssetsNoncurrent
|
$4.72M | USD | Point-in-time |
| Total assets |
Assets
|
$948.17M | USD | Point-in-time |
| Total assets |
Assets
|
$962.53M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$24.38M | USD | Point-in-time |
| Accounts payable |
AccountsPayableCurrent
|
$16.20M | USD | Point-in-time |
| Accrued compensation |
DeferredCompensationLiabilityCurrent
|
$18.56M | USD | Point-in-time |
| Accrued compensation |
DeferredCompensationLiabilityCurrent
|
$22.93M | USD | Point-in-time |
| Accrued expenses |
AccruedLiabilitiesCurrent
|
$23.07M | USD | Point-in-time |
| Accrued expenses |
AccruedLiabilitiesCurrent
|
$25.70M | USD | Point-in-time |
| Deferred revenue |
DeferredRevenueCurrent
|
$11.94M | USD | Point-in-time |
| Deferred revenue |
DeferredRevenueCurrent
|
$12.28M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$82.32M | USD | Point-in-time |
| Total current liabilities |
LiabilitiesCurrent
|
$72.73M | USD | Point-in-time |
| Long-term operating lease liabilities |
OperatingLeaseLiabilityNoncurrent
|
$33.77M | USD | Point-in-time |
| Long-term operating lease liabilities |
OperatingLeaseLiabilityNoncurrent
|
$33.26M | USD | Point-in-time |
| Obligation related to royalty |
AccruedRoyaltiesNoncurrent
|
$6.88M | USD | Point-in-time |
| Obligation related to royalty |
AccruedRoyaltiesNoncurrent
|
- | USD | Point-in-time |
| Other long-term liabilities |
OtherLiabilitiesNoncurrent
|
$1.67M | USD | Point-in-time |
| Other long-term liabilities |
OtherLiabilitiesNoncurrent
|
$1.46M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$117.55M | USD | Point-in-time |
| Total liabilities |
Liabilities
|
$114.54M | USD | Point-in-time |
| Redeemable noncontrolling interest |
RedeemableNoncontrollingInterestEquityCarryingAmount
|
$45.50M | USD | Point-in-time |
| Redeemable noncontrolling interest |
RedeemableNoncontrollingInterestEquityCarryingAmount
|
$49.60M | USD | Point-in-time |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 94,509,011 and 94,261,414 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively |
CommonStockValueOutstanding
|
$1.00K | USD | Point-in-time |
| Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 94,509,011 and 94,261,414 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively |
CommonStockValueOutstanding
|
$1.00K | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$1.15B | USD | Point-in-time |
| Additional paid-in capital |
AdditionalPaidInCapital
|
$1.16B | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$1.11M | USD | Point-in-time |
| Accumulated other comprehensive income |
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
$7.71M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-352.81M | USD | Point-in-time |
| Accumulated deficit |
RetainedEarningsAccumulatedDeficit
|
$-380.54M | USD | Point-in-time |
| Total Stockholders Equity |
StockholdersEquity
|
$785.11M | USD | Point-in-time |
| Total Stockholders Equity |
StockholdersEquity
|
$483.15M | USD | Point-in-time |
| Total Stockholders Equity |
StockholdersEquity
|
$798.39M | USD | Point-in-time |
| Total Stockholders Equity |
StockholdersEquity
|
$468.13M | USD | Point-in-time |
| Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity |
LiabilitiesAndStockholdersEquity
|
$948.17M | USD | Point-in-time |
| Total Liabilities, Redeemable Noncontrolling Interest and Stockholders Equity |
LiabilitiesAndStockholdersEquity
|
$962.53M | USD | Point-in-time |
Income Statement
40 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Precision oncology testing |
RevenuefromPrecisionOncologyTesting
|
$28.84M | USD | 1 Quarter |
| Precision oncology testing |
RevenuefromPrecisionOncologyTesting
|
$60.25M | USD | 1 Quarter |
| Development services |
RevenuefromDevelopmentServices
|
$7.82M | USD | 1 Quarter |
| Development services |
RevenuefromDevelopmentServices
|
$7.26M | USD | 1 Quarter |
| Total revenue |
Revenues
|
$67.51M | USD | 1 Quarter |
| Total revenue |
Revenues
|
$36.66M | USD | 1 Quarter |
| Cost of precision oncology testing |
CostsofPrecisionOncologyTesting
|
$11.02M | USD | 1 Quarter |
| Cost of precision oncology testing |
CostsofPrecisionOncologyTesting
|
$18.19M | USD | 1 Quarter |
| Cost of development services |
CostofDevelopmentServices
|
$2.31M | USD | 1 Quarter |
| Cost of development services |
CostofDevelopmentServices
|
$2.51M | USD | 1 Quarter |
| Research and development expense |
ResearchAndDevelopmentExpense
|
$37.02M | USD | 1 Quarter |
| Research and development expense |
ResearchAndDevelopmentExpense
|
$16.32M | USD | 1 Quarter |
| Sales and marketing expense |
SellingAndMarketingExpense
|
$25.11M | USD | 1 Quarter |
| Sales and marketing expense |
SellingAndMarketingExpense
|
$17.81M | USD | 1 Quarter |
| General and administrative expense |
GeneralAndAdministrativeExpense
|
$19.79M | USD | 1 Quarter |
| General and administrative expense |
GeneralAndAdministrativeExpense
|
$12.66M | USD | 1 Quarter |
| Total costs and operating expenses |
CostsAndExpenses
|
$60.32M | USD | 1 Quarter |
| Total costs and operating expenses |
CostsAndExpenses
|
$102.42M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-34.91M | USD | 1 Quarter |
| Loss from operations |
OperatingIncomeLoss
|
$-23.66M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$3.32M | USD | 1 Quarter |
| Interest income |
InvestmentIncomeInterest
|
$2.48M | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$293.00K | USD | 1 Quarter |
| Interest expense |
InterestExpense
|
$12.00K | USD | 1 Quarter |
| Other (expense) income, net |
OtherNonoperatingIncomeExpense
|
$-209.00K | USD | 1 Quarter |
| Other (expense) income, net |
OtherNonoperatingIncomeExpense
|
$147.00K | USD | 1 Quarter |
| Loss before provision for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$-21.32M | USD | 1 Quarter |
| Loss before provision for income taxes |
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
$-31.82M | USD | 1 Quarter |
| Provision for income taxes |
IncomeTaxExpenseBenefit
|
$14.00K | USD | 1 Quarter |
| Provision for income taxes |
IncomeTaxExpenseBenefit
|
$26.00K | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-21.35M | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-31.83M | USD | 1 Quarter |
| Adjustment of redeemable noncontrolling interest |
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
|
$-4.10M | USD | 1 Quarter |
| Adjustment of redeemable noncontrolling interest |
NetIncomeLossAttributableToRedeemableNoncontrollingInterest
|
$4.70M | USD | 1 Quarter |
| Net loss attributable to Guardant Health, Inc. common stockholders |
NetIncomeLossAvailableToCommonStockholdersBasic
|
$-27.73M | USD | 1 Quarter |
| Net loss attributable to Guardant Health, Inc. common stockholders |
NetIncomeLossAvailableToCommonStockholdersBasic
|
$-26.05M | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic and diluted (in usd per share) |
EarningsPerShareBasicAndDiluted
|
$-0.29 | USD | 1 Quarter |
| Net loss per share attributable to common stockholders, basic and diluted (in usd per share) |
EarningsPerShareBasicAndDiluted
|
$-0.30 | USD | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) |
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
85.94M | shares | 1 Quarter |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) |
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
94.38M | shares | 1 Quarter |
Cash Flow Statement
78 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Net loss |
ProfitLoss
|
$-21.35M | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-31.83M | USD | 1 Quarter |
| Depreciation and amortization |
DepreciationDepletionAndAmortization
|
$2.35M | USD | 1 Quarter |
| Depreciation and amortization |
DepreciationDepletionAndAmortization
|
$3.30M | USD | 1 Quarter |
| Amortization of right-of-use assets |
AmortizationOfRightOfUseAsset
|
$1.50M | USD | 1 Quarter |
| Amortization of right-of-use assets |
AmortizationOfRightOfUseAsset
|
$802.00K | USD | 1 Quarter |
| Charge of in-process research and development costs with no alternative future use |
ChargeOfInProcessResearchAndDevelopment
|
- | USD | 1 Quarter |
| Charge of in-process research and development costs with no alternative future use |
ChargeOfInProcessResearchAndDevelopment
|
$8.50M | USD | 1 Quarter |
| Unrealized translation gains (loss) on obligation related to royalty |
UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
|
- | USD | 1 Quarter |
| Unrealized translation gains (loss) on obligation related to royalty |
UnrealizedTranslationsGainLossOnObligationRelatedToRoyalty
|
$144.00K | USD | 1 Quarter |
| Re-valuation of contingent consideration |
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
$-190.00K | USD | 1 Quarter |
| Re-valuation of contingent consideration |
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
- | USD | 1 Quarter |
| Non-cash stock-based compensation |
ShareBasedCompensation
|
$6.34M | USD | 1 Quarter |
| Non-cash stock-based compensation |
ShareBasedCompensation
|
$3.18M | USD | 1 Quarter |
| Amortization of premium (discount) on marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$553.00K | USD | 1 Quarter |
| Amortization of premium (discount) on marketable securities |
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
$-580.00K | USD | 1 Quarter |
| Others |
OtherOperatingActivitiesCashFlowStatement
|
$56.00K | USD | 1 Quarter |
| Others |
OtherOperatingActivitiesCashFlowStatement
|
- | USD | 1 Quarter |
| Accounts receivable, net |
IncreaseDecreaseInAccountsReceivable
|
$179.00K | USD | 1 Quarter |
| Accounts receivable, net |
IncreaseDecreaseInAccountsReceivable
|
$-11.61M | USD | 1 Quarter |
| Inventory |
IncreaseDecreaseInInventories
|
$9.97M | USD | 1 Quarter |
| Inventory |
IncreaseDecreaseInInventories
|
$1.12M | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$2.60M | USD | 1 Quarter |
| Prepaid expenses and other current assets |
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
$947.00K | USD | 1 Quarter |
| Other assets |
IncreaseDecreaseInOtherOperatingAssets
|
$833.00K | USD | 1 Quarter |
| Other assets |
IncreaseDecreaseInOtherOperatingAssets
|
$-161.00K | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$9.49M | USD | 1 Quarter |
| Accounts payable |
IncreaseDecreaseInAccountsPayable
|
$-2.61M | USD | 1 Quarter |
| Accrued compensation |
IncreaseDecreaseInEmployeeRelatedLiabilities
|
$1.70M | USD | 1 Quarter |
| Accrued compensation |
IncreaseDecreaseInEmployeeRelatedLiabilities
|
$4.38M | USD | 1 Quarter |
| Accrued expenses |
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
$2.31M | USD | 1 Quarter |
| Accrued expenses |
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
$-660.00K | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiabilities
|
$-1.86M | USD | 1 Quarter |
| Operating lease liabilities |
IncreaseDecreaseInOperatingLeaseLiabilities
|
$329.00K | USD | 1 Quarter |
| Deferred revenue |
IncreaseDecreaseInDeferredRevenue
|
$975.00K | USD | 1 Quarter |
| Deferred revenue |
IncreaseDecreaseInDeferredRevenue
|
$-341.00K | USD | 1 Quarter |
| Other liabilities |
IncreaseDecreaseInOtherOperatingLiabilities
|
$36.00K | USD | 1 Quarter |
| Other liabilities |
IncreaseDecreaseInOtherOperatingLiabilities
|
- | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-13.28M | USD | 1 Quarter |
| Net cash used in operating activities |
NetCashProvidedByUsedInOperatingActivities
|
$-4.30M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$55.76M | USD | 1 Quarter |
| Purchases of marketable securities |
PaymentsToAcquireMarketableSecurities
|
$45.97M | USD | 1 Quarter |
| Maturity of marketable securities |
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
$64.00M | USD | 1 Quarter |
| Maturity of marketable securities |
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
$104.05M | USD | 1 Quarter |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$2.71M | USD | 1 Quarter |
| Purchases of property and equipment |
PaymentsToAcquirePropertyPlantAndEquipment
|
$9.60M | USD | 1 Quarter |
| Purchase of intangible assets |
PaymentsToAcquireIntangibleAssets
|
$17.89M | USD | 1 Quarter |
| Purchase of intangible assets |
PaymentsToAcquireIntangibleAssets
|
- | USD | 1 Quarter |
| Net cash provided by investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$15.33M | USD | 1 Quarter |
| Net cash provided by investing activities |
NetCashProvidedByUsedInInvestingActivities
|
$20.80M | USD | 1 Quarter |
| Payments made on royalty obligations |
PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
|
- | USD | 1 Quarter |
| Payments made on royalty obligations |
PaymentRelatedtoSettlementofDebtandBuyoutofRoyaltyObligations
|
$73.00K | USD | 1 Quarter |
| Payments made on capital lease obligations |
RepaymentsOfLongTermCapitalLeaseObligations
|
$38.00K | USD | 1 Quarter |
| Payments made on capital lease obligations |
RepaymentsOfLongTermCapitalLeaseObligations
|
$21.00K | USD | 1 Quarter |
| Proceeds from issuance of common stock upon exercise of stock options |
ProceedsFromStockOptionsExercised
|
$1.50M | USD | 1 Quarter |
| Proceeds from issuance of common stock upon exercise of stock options |
ProceedsFromStockOptionsExercised
|
$538.00K | USD | 1 Quarter |
| Proceeds from issuances of common stock under employee stock purchase plan |
ProceedsFromStockPlans
|
$1.93M | USD | 1 Quarter |
| Proceeds from issuances of common stock under employee stock purchase plan |
ProceedsFromStockPlans
|
- | USD | 1 Quarter |
| Payment of offering costs related to initial public offering and follow-on offering |
PaymentsOfStockIssuanceCosts
|
- | USD | 1 Quarter |
| Payment of offering costs related to initial public offering and follow-on offering |
PaymentsOfStockIssuanceCosts
|
$89.00K | USD | 1 Quarter |
| Net cash provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$2.29M | USD | 1 Quarter |
| Net cash provided by financing activities |
NetCashProvidedByUsedInFinancingActivities
|
$1.47M | USD | 1 Quarter |
| Net effect of foreign exchange rate changes on cash and cash equivalents |
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$-69.00K | USD | 1 Quarter |
| Net effect of foreign exchange rate changes on cash and cash equivalents |
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$23.00K | USD | 1 Quarter |
| Net increase in cash and cash equivalents |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$9.01M | USD | 1 Quarter |
| Net increase in cash and cash equivalents |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
$13.24M | USD | 1 Quarter |
| Cash and cash equivalentsBeginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$143.23M | USD | Point-in-time |
| Cash and cash equivalentsBeginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$152.24M | USD | Point-in-time |
| Cash and cash equivalentsBeginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$140.54M | USD | Point-in-time |
| Cash and cash equivalentsBeginning of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$153.79M | USD | Point-in-time |
| Cash and cash equivalentsEnd of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$143.23M | USD | Point-in-time |
| Cash and cash equivalentsEnd of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$152.24M | USD | Point-in-time |
| Cash and cash equivalentsEnd of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$140.54M | USD | Point-in-time |
| Cash and cash equivalentsEnd of period |
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
$153.79M | USD | Point-in-time |
| Operating lease liabilities arising from obtaining right-of-use assets |
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
- | USD | 1 Quarter |
| Operating lease liabilities arising from obtaining right-of-use assets |
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
$1.96M | USD | 1 Quarter |
| Purchases of property and equipment included in accounts payable and accrued expenses |
CapitalExpendituresIncurredButNotYetPaid
|
$490.00K | USD | 1 Quarter |
| Purchases of property and equipment included in accounts payable and accrued expenses |
CapitalExpendituresIncurredButNotYetPaid
|
$1.36M | USD | 1 Quarter |
Stockholders Equity
22 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Adjustment of redeemable noncontrolling interest |
ReclassificationsOfTemporaryToPermanentEquity
|
$-4.70M | USD | 1 Quarter |
| Adjustment of redeemable noncontrolling interest |
ReclassificationsOfTemporaryToPermanentEquity
|
$4.10M | USD | 1 Quarter |
| Beginning balance |
StockholdersEquity
|
$785.11M | USD | Point-in-time |
| Beginning balance |
StockholdersEquity
|
$483.15M | USD | Point-in-time |
| Beginning balance |
StockholdersEquity
|
$798.39M | USD | Point-in-time |
| Beginning balance |
StockholdersEquity
|
$468.13M | USD | Point-in-time |
| Issuance of common stock upon exercise of stock options, shares |
StockIssuedDuringPeriodSharesStockOptionsExercised
|
242,003.00 | shares | 1 Quarter |
| Issuance of common stock upon exercise of stock options |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$1.50M | USD | 1 Quarter |
| Issuance of common stock upon exercise of stock options |
StockIssuedDuringPeriodValueStockOptionsExercised
|
$538.00K | USD | 1 Quarter |
| Vesting of common stock exercised early |
StockIssuedDuringPeriodValueStockOptionsExercisedEarly
|
$56.00K | USD | 1 Quarter |
| Vesting of common stock exercised early |
StockIssuedDuringPeriodValueStockOptionsExercisedEarly
|
$13.00K | USD | 1 Quarter |
| Common stock issued under employee stock purchase plan |
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
$1.93M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$6.34M | USD | 1 Quarter |
| Stock-based compensation |
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
$3.18M | USD | 1 Quarter |
| Other comprehensive gain (loss), net of tax impact |
OtherComprehensiveIncomeLossNetOfTax
|
$6.59M | USD | 1 Quarter |
| Other comprehensive gain (loss), net of tax impact |
OtherComprehensiveIncomeLossNetOfTax
|
$416.00K | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-21.35M | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-31.83M | USD | 1 Quarter |
| Ending balance |
StockholdersEquity
|
$785.11M | USD | Point-in-time |
| Ending balance |
StockholdersEquity
|
$483.15M | USD | Point-in-time |
| Ending balance |
StockholdersEquity
|
$798.39M | USD | Point-in-time |
| Ending balance |
StockholdersEquity
|
$468.13M | USD | Point-in-time |
Comprehensive Income
14 line items
| Line Item | Tag | Value | Unit | Period |
|---|---|---|---|---|
| Net loss |
ProfitLoss
|
$-21.35M | USD | 1 Quarter |
| Net loss |
ProfitLoss
|
$-31.83M | USD | 1 Quarter |
| Unrealized gain on available-for-sale securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$6.57M | USD | 1 Quarter |
| Unrealized gain on available-for-sale securities |
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
$485.00K | USD | 1 Quarter |
| Foreign currency translation adjustments |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
$-69.00K | USD | 1 Quarter |
| Foreign currency translation adjustments |
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
|
$23.00K | USD | 1 Quarter |
| Other comprehensive income |
OtherComprehensiveIncomeLossNetOfTax
|
$6.59M | USD | 1 Quarter |
| Other comprehensive income |
OtherComprehensiveIncomeLossNetOfTax
|
$416.00K | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
$-20.93M | USD | 1 Quarter |
| Comprehensive loss |
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
|
$-25.23M | USD | 1 Quarter |
| Comprehensive gain (loss) attributable to redeemable noncontrolling interest |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
|
$4.70M | USD | 1 Quarter |
| Comprehensive gain (loss) attributable to redeemable noncontrolling interest |
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest
|
$-4.10M | USD | 1 Quarter |
| Comprehensive loss attributable to Guardant Health, Inc. |
ComprehensiveIncomeNetOfTax
|
$-21.14M | USD | 1 Quarter |
| Comprehensive loss attributable to Guardant Health, Inc. |
ComprehensiveIncomeNetOfTax
|
$-25.64M | USD | 1 Quarter |
Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.